TY - JOUR
T1 - Comparison of peripheral leukocyte parameters in patients receiving conventionally and hypofractionated radiotherapy schemes for the treatment of newly diagnosed glioblastoma
AU - Greenlund, Lindsey
AU - Shanley, Ryan
AU - Mulford, Kellen
AU - Neil, Elizabeth C.
AU - Lawrence, Jessica
AU - Arnold, Susan
AU - Olin, Michael
AU - Pluhar, G. Elizabeth
AU - Venteicher, Andrew S.
AU - Chen, Clark C.
AU - Ferreira, Clara
AU - Reynolds, Margaret
AU - Cho, L. Chinsoo
AU - Wilke, Christopher
AU - Shoo, B. Aika
AU - Yuan, Jianling
AU - Dusenbery, Kathryn
AU - Kleinberg, Lawrence R.
AU - Terezakis, Stephanie A.
AU - Sloan, Lindsey
N1 - Publisher Copyright:
Copyright © 2023 Greenlund, Shanley, Mulford, Neil, Lawrence, Arnold, Olin, Pluhar, Venteicher, Chen, Ferreira, Reynolds, Cho, Wilke, Shoo, Yuan, Dusenbery, Kleinberg, Terezakis and Sloan.
PY - 2023
Y1 - 2023
N2 - Introduction: Treatment for glioblastomas, aggressive and nearly uniformly fatal brain tumors, provide limited long-term success. Immunosuppression by myeloid cells in both the tumor microenvironment and systemic circulation are believed to contribute to this treatment resistance. Standard multi-modality therapy includes conventionally fractionated radiotherapy over 6 weeks; however, hypofractionated radiotherapy over 3 weeks or less may be appropriate for older patients or populations with poor performance status. Lymphocyte concentration changes have been reported in patients with glioblastoma; however, monocytes are likely a key cell type contributing to immunosuppression in glioblastoma. Peripheral monocyte concentration changes in patients receiving commonly employed radiation fractionation schemes are unknown. Methods: To determine the effect of conventionally fractionated and hypofractionated radiotherapy on complete blood cell leukocyte parameters, retrospective longitudinal concentrations were compared prior to, during, and following standard chemoradiation treatment. Results: This study is the first to report increased monocyte concentrations and decreased lymphocyte concentrations in patients treated with conventionally fractionated radiotherapy compared to hypofractionated radiotherapy. Discussion: Understanding the impact of fractionation on peripheral blood leukocytes is important to inform selection of dose fractionation schemes for patients receiving radiotherapy.
AB - Introduction: Treatment for glioblastomas, aggressive and nearly uniformly fatal brain tumors, provide limited long-term success. Immunosuppression by myeloid cells in both the tumor microenvironment and systemic circulation are believed to contribute to this treatment resistance. Standard multi-modality therapy includes conventionally fractionated radiotherapy over 6 weeks; however, hypofractionated radiotherapy over 3 weeks or less may be appropriate for older patients or populations with poor performance status. Lymphocyte concentration changes have been reported in patients with glioblastoma; however, monocytes are likely a key cell type contributing to immunosuppression in glioblastoma. Peripheral monocyte concentration changes in patients receiving commonly employed radiation fractionation schemes are unknown. Methods: To determine the effect of conventionally fractionated and hypofractionated radiotherapy on complete blood cell leukocyte parameters, retrospective longitudinal concentrations were compared prior to, during, and following standard chemoradiation treatment. Results: This study is the first to report increased monocyte concentrations and decreased lymphocyte concentrations in patients treated with conventionally fractionated radiotherapy compared to hypofractionated radiotherapy. Discussion: Understanding the impact of fractionation on peripheral blood leukocytes is important to inform selection of dose fractionation schemes for patients receiving radiotherapy.
KW - conventionally fractionated radiotherapy
KW - fractionation
KW - glioblastoma
KW - hypofractionated radiotherapy
KW - leukocytes
UR - http://www.scopus.com/inward/record.url?scp=85176919652&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85176919652&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2023.1284118
DO - 10.3389/fimmu.2023.1284118
M3 - Article
C2 - 38022656
AN - SCOPUS:85176919652
SN - 1664-3224
VL - 14
JO - Frontiers in immunology
JF - Frontiers in immunology
M1 - 1284118
ER -